首页> 外文期刊>Therapeutic Drug Monitoring >Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
【24h】

Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation

机译:肾移植后第一年的淋巴细胞中标准粒素的纵向研究

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Tacrolimus (TAC) is an immunosuppressive drug used after organ transplantation. Dosing is adjusted using whole blood (WB-TAC) measurements. Patients within the therapeutic WB-TAC window still experience rejections and adverse effects. Alternative monitoring methods are therefore warranted. The authors developed a method for measuring TAC in peripheral blood mononuclear cell (PBMC) isolates (PBMC-TAC) and performed a pharmacokinetic study in a cohort of kidney transplant patients during the first year after transplantation.
机译:简介:Tacrolimus(TAC)是器官移植后使用的免疫抑制药物。 使用全血(WB-TAC)测量调整给药。 治疗WB-TAC窗口中的患者仍然体验抑制和不利影响。 因此需要替代的监测方法。 作者开发了一种用于测量外周血单核细胞(PBMC)分离株(PBMC-TAC)的TAC的方法,并在移植后的第一年进行肾移植患者队列的药代动力学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号